Esperion(ESPR) - 2023 Q3 - Earnings Call Presentation
Esperion(ESPR)2023-11-07 15:51• On max tolerated statin Important Safety Information | --- | --- | |-------------------------------------|----------------------| | FY 2023 R&D Guidance | $100 - 110 Million | | FY 2023 SG&A Guidance | $125 - 135 Million | | FY 2023 Op Ex Guidance1 | $225 - 245 Million | | Q3 2023 Common Shares Outstanding 2 | 112.1 Million | © 2023 Esperion. All/Rights Reserved – Do not copy or distribute. 13 © 2023 Esperion. All Rights Reserved – Do not copy or distribute. Corporate Update • Filed Rule 12(c) motion, req ...